Literature DB >> 9667061

Psychosomatic aspects of Cushing's disease.

N Sonino1, G A Fava.   

Abstract

The past decades have witnessed an increasing understanding of the psychosomatic aspects of Cushing's disease. Stressful life events were found to precede its onset in controlled studies. Major depression is a common, life-threatening complication of Cushing's syndrome, regardless of its etiology. The presence of depression connotes severity of clinical presentation and entails prognostic value (patients with hypothalamic-pituitary forms are more likely to relapse after successful treatment if they presented with depression). Quality of life of patients with Cushing's disease is seriously compromised. Recovery has a natural course to run and may be considerably influenced by affective responses based on highly individualized psychological assets and liabilities. The psychobiological correlates of Cushing's disease have considerable etiological, clinical and therapeutic implications. Such implications also extend over the nonendocrine forms of major depression.

Entities:  

Mesh:

Year:  1998        PMID: 9667061     DOI: 10.1159/000012274

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  16 in total

1.  A specific nursing educational program in patients with Cushing's syndrome.

Authors:  M Antonia Martínez-Momblán; Carmen Gómez; Alicia Santos; Nuria Porta; Julia Esteve; Inmaculada Úbeda; Irene Halperin; Beatriz Campillo; Montserrat Guillaumet; Susan M Webb; Eugenia Resmini
Journal:  Endocrine       Date:  2015-09-23       Impact factor: 3.633

2.  Clinical score system in the treatment of Cushing's disease: failure to identify discriminative variables from the German Cushing's Registry.

Authors:  Mareike R Stieg; Matthias K Auer; Christina Berr; Julia Fazel; Martin Reincke; Stephanie Zopp; Alexander Yassouridis; Günter K Stalla
Journal:  Pituitary       Date:  2019-04       Impact factor: 4.107

Review 3.  Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.

Authors:  N Sonino; G A Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

Review 5.  Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management.

Authors:  Alicia Santos; Eugenia Resmini; Juan Carlos Pascual; Iris Crespo; Susan M Webb
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

6.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.

Authors:  R van der Pas; C de Bruin; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M Zelissen; F H de Jong; A J van der Lely; W W de Herder; S M Webb; S W J Lamberts; L J Hofland; R A Feelders
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

7.  Evaluation of depression, quality of life and body image in patients with Cushing's disease.

Authors:  Nilufer Alcalar; Sedat Ozkan; Pinar Kadioglu; Ozlem Celik; Penbe Cagatay; Baris Kucukyuruk; Nurperi Gazioglu
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

8.  Outcome of adrenalectomy for Cushing's syndrome: experience from a tertiary care center.

Authors:  Anand Kumar Mishra; Amit Agarwal; Sushil Gupta; G Agarwal; A K Verma; S K Mishra
Journal:  World J Surg       Date:  2007-05-30       Impact factor: 3.352

Review 9.  Improving Quality of Life in Patients with Pituitary Tumours.

Authors:  Iris Crespo; Alicia Santos; Eugenia Resmini; Elena Valassi; Maria Antonia Martínez-Momblán; Susan M Webb
Journal:  Eur Endocrinol       Date:  2013-03-15

10.  ARE THERE RELIABLE PREDICTORS FOR THE IMPAIRED QUALITY OF LIFE IN PATIENTS WITH CUSHING'S SYNDROME?

Authors:  A B Nankova; M Yaneva; A Elenkova; K Kalinov; S Zacharieva
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.